BRTX BioRestorative Therapies, Inc.
Price Chart
Executive Summary
BioRestorative Therapies filed an 8-K reporting the entry into new 3-year employment agreements with CEO Lance Alstodt (salary unchanged at $600,000) and CFO Robert Kristal (salary unchanged at $350,000), effective May 27, 2026. Separately, at a Special Meeting on May 26, 2026, stockholders approved a massive increase in authorized common shares from 75 million to 1.5 billion — a 20x expansion that creates massive dilution overhang for the $12M market cap company. The authorized share increase is the material event; the executive employment agreements are routine.
Actionable Insight
The 20x authorized share increase is a clear signal that the company plans significant equity issuance, likely for capital raises or M&A. With a $12M market cap and 1.5B authorized shares, the potential for extreme dilution is severe. Monitor for a follow-on offering filing (S-1 or prospectus supplement) in the coming weeks. The executive employment agreements are routine and do not change the bearish read from the authorized share expansion.
Key Facts
- Stockholders approved increasing authorized common shares from 75,000,000 to 1,500,000,000 — a 20x increase.
- Vote was 9,868,606 For, 2,389,059 Against, 179,207 Abstentions — passed with ~79% of votes cast in favor.
- CEO Lance Alstodt entered a 3-year employment agreement with $600,000 annual salary (unchanged).
- CFO Robert Kristal entered a 3-year employment agreement with $350,000 annual salary (unchanged).
- Both agreements include single-trigger change-in-control vesting of all equity awards and cash severance equal to 2x (Alstodt) or 1x (Kristal) salary plus max bonus.
- Market cap is approximately $12M; the authorized share count now exceeds market cap by orders of magnitude.
Financial Impact
Authorized shares increased from 75M to 1.5B — a 1,900% increase — enabling massive future dilution at a company with a ~$12M market cap.
Risk Factors
- Massive authorized share increase enables extreme dilution — potential for offerings that could reduce existing holders' stake to near-zero.
- Company has a history of poor stock performance (prior reports show negative T+5 and T+20 returns).
- No financial results or guidance provided in this filing — the share authorization without a disclosed use case increases uncertainty.
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001021771-26-000084 |
| Exhibit: ex99_1.htm | 0001021771-26-000084 |
| Document: brtx-20260529.htm | 0001021771-26-000084 |
| Document: 0001021771-26-000084-index-headers.html | 0001021771-26-000084 |
| Document: 0001021771-26-000084-index.html | 0001021771-26-000084 |
| Document: 0001021771-26-000084.txt | 0001021771-26-000084 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
8-K
| $0.3706 awaiting T+5 | awaiting T+5 | — | $0.3525 (+4.88%) |
|
May 29, 2026
14d ago
|
8-K
| $0.4064 $0.4050 | ▲ +0.34% | ▼ −2.41% | $0.3525 (+13.26%) |
|
May 1, 2026
6w ago
|
8-K
| $0.2420 $0.2012 | ▼ −16.86% | ▼ −19.80% | $0.3525 (+45.66%) |
|
Apr 7, 2026
9w ago
|
Press Release
| $0.2507 $0.2460 | ▼ −1.87% | ▼ −7.20% | $0.3525 (+40.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access